

Influenza Reagent Influenza Virus Infectious NYMC-X-425A (A/Croatia/10136RV/2023) (H3N2) NIBSC code: 24/162 Instructions for use (Version 2.0, Dated 17/10/2024)

§

1. INTENDED USE

Reagent 24/162 was prepared from NYMC-X-425A (H3N2), a reassortant of A/Croatia/10136RV/2023 (H3N2) and A/PuertoRico/8/34 (H1N1), which was processed in 250 μ I volumes as liquid stock. The derivation and known passage history of 24/162 are attached.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material.

4. CONTENTS

Country of origin of biological material: United Kingdom. Each ampoule contains $250\mu I$ (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen's eggs.

5. STORAGE

Store in the dark at -70°C or below.

Material type: Liquid – will be shipped according to the storage and shipping conditions of the product

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

Ready to use.

8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

N/A.

10. ACKNOWLEDGEMENTS N/A.

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards,

UK Official Medicines Control Laboratory



11. FURTHER INFORMATION

Further information can be obtained as follows; This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/ JCTLM Higher order reference materials: http://www.bipm.org/en/committees/jc/jctlm/ Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC: http://www.nibsc.org/products/ordering.aspx NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties					
Physical appearance: Clear liquid		Corrosive:	No		
Stable: Yes		Oxidising:	No		
Hygroscopi No c:		Irritant:	No		
Flammable: No	lammable: No		Handling: See caution, Section 2		
Other Live influenza virus (specify):					
Toxicological properties					
		lihood of influenza virus, avoid alation			
Effects of ingestion: Not		established, avoid ingestion			
Effects of skin	Not established, avoid contact with				
absorption:	skin				
Suggested First Aid					
Inhalation: Seek medical advice					
Ingestion: Seek medical advice					
Contact with Wash with copious amounts of water. Seek					
eyes: medical advice					
Contact with Wash thoroughly with water. skin:					



Action on Spillage and Method of Disposal

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water.

Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the



exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY
Country of origin for customs purposes*: United Kingdom
* Defined as the country where the goods have been
produced and/or sufficiently processed to be classed as
originating from the country of supply, for example a change
of state such as freeze-drying.
Net weight: 0.25g per vial
Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable.
Attached: No

NYMC-X-425A (H3N2) Passage History

Cumulative number of passages	Passage numbers at each stage	Lot	Laboratory
E10	E2/E8	E6614	NYMC, USA
E11	E2/E8/E1	48680	MHRA, UK

*The HA titre of this virus using 0.7% guinea pig red blood cells is 512. The infectious titre is unknown.

Sterility: no visible contamination was detected in a variety of media (tryptone soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates), after 14 days incubation.


The HA and NA sequence of this virus are available on GISAID, with the accession number EPI_ISL_19481596.





Derivation of NYMC X-425A A/Croatia/10136RV/2023 (H3N2) with A/PR/8/34 High Yield A H3N2 Reassortant (5:3) with A/PR/8/34 M, PB2, PA, NS and NP genes and A/Croatia/10136/RV/2023 HA, NA and PB1 genes


Exp. # 4922 A/Croatia/10136/RV/2023, H3N2 240929 26/03/2024 E2 (Am1Al1)



National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory

Medicines & Healthcare products Regulatory Agency





PB1, HA and NA genes were identified as A/Croatia/10136/RV/2023 by RT-PCR/RFLP gene analysis. The M, PB2, PA, NS and NP genes were identified as A/PR/8/34 by RT-PCR/RFLP analysis.

SPF eggs were used for all reassortant passages.

Virus seed was shown to be sterile. Sterility testing was performed by streaking the sample on blood agar plates and incubating for 48 hours at 37 °C.

Titers performed with guinea pig red blood cells.